/images/ppid_a911dc6a-image-177739102586298391.webp)
Shares of Cohance Lifesciences surged 20 per cent in early trade on Monday after the pharmaceutical company announced the appointment of Umang Vohra as executive chairman and group CEO. The stock jumped to Rs 432.1 apiece on the NSE, against its previous close of Rs 360.1, as investors cheered the leadership change and growth prospects.
The company said Vohra will take charge as executive chairman from May 1, 2026, while he will assume the role of Group CEO from May 20, 2026.
He succeeds Vivek Sharma, who is stepping down for personal reasons. Sharma will continue as an advisor to the company for the next nine months to ensure a smooth transition.
In a statement, the company said the appointment reflects a strategic decision by the board to bring
in a leader suited for the company’s transformation and next phase of growth.
As of last Friday’s close, shares of Cohance Lifesciences were the third-worst performers on the Nifty Smallcap index, with losses of 31%.
Why Markets Reacted Positively
Vohra is regarded as one of the most experienced leaders in India’s pharmaceutical industry. Most recently, he served as CEO and managing director of Cipla Limited, where he led the company’s transformation over the past decade into a diversified global pharma enterprise.
Market participants appear to have welcomed the move, betting that his leadership could accelerate growth, improve global partnerships and strengthen Cohance’s position in the fast-growing CDMO segment.
What Cohance Lifesciences Does
Cohance Lifesciences operates a technology-driven integrated CDMO (Contract Development and Manufacturing Organisation) platform. The company focuses on complex chemistry, ADCs, oligonucleotides, advanced API development and specialty performance materials.
It has integrated R&D centres, more than 400 scientists, and partnerships with global pharmaceutical innovators.
Management Commentary
Vohra said he is excited to join Cohance and sees strong long-term value creation potential in the platform. He added that the company’s technology offerings, research talent and leadership team provide a solid base for future growth.
“I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike. Vivek Sharma said, “Over the past few years, we have built a strong foundation for Cohance — integrating businesses, strengthening the leadership team, and establishing the platform’s identity as a science-led CDMO. I am proud of what the team has achieved and confident that the platform is well positioned for its next chapter. I wish Umang and the entire Cohance team every success as they take the company forward,” he stated.
Pankaj Patwari, managing director at Advent International, said the company would benefit from Vohra’s owner-manager mindset, operational depth and track record of leading large-scale transformations.
“I am excited to welcome Umang to the Cohance family. The platform will greatly benefit from a leader like Umang, who brings an owner manager mindset, and who can build on the business’s scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture. Umang is one of the most respected leaders in the Indian pharmaceutical industry. He brings global stature, operational depth, and a track record of building and leading large-scale transformations. We are delighted to partner with him as we continue to grow the business together,” he said.
